One lung cancer drug receives NHS England approval, while another is not

8 July 2019
cancer_research_uk_big

A targeted drug has been accepted for routine use on the National Health Service (NHS) in England for some adults with untreated, advanced lung cancer. But another precision drug, for the same group of patients, has been rejected due to questions over its cost-effectiveness, noted that charity Cancer Research UK.

The two drugs – Pfizer’s (NYSE: PFE) Vizimpro (dacomitinib) and AstraZeneca’s (LSE: AZN) Tagrisso (osimertinib – were each being considered as initial treatments for patients whose non-small cell lung cancer (NSCLC) had begun to spread to other parts of the body.

Both drugs, along with several others already used in the NHS to treat lung cancer, target growth signals fuelled by the EGFR molecule inside cells. By switching off these signals, the drugs are designed to stall cell growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology